Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic Syndrome

AUTOR(ES)

Mache, Christoph J.

FONTE

American Society of Nephrology

RESUMO

Background and objectives: Atypical hemolytic uremic syndrome (aHUS) is associated with a congenital or acquired dysregulation of the complement alternative pathway that leads to continuous complement activation on host cells causing inflammation and damage. Eculizumab, a humanized mAb against complement protein C5, inhibits activation of the terminal complement pathway.

Documentos Relacionados

• Structural and Functional Characterization of Factor H Mutations Associated with Atypical Hemolytic Uremic Syndrome
• Clustering of Missense Mutations in the C-Terminal Region of Factor H in Atypical Hemolytic Uremic Syndrome
• A Large Family with a Gain-of-Function Mutation of Complement C3 Predisposing to Atypical Hemolytic Uremic Syndrome, Microhematuria, Hypertension and Chronic Renal Failure
• Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome
• Escherichia coli infections and hemolytic-uremic syndrome